Why the study?
Despite various antihypertensive drugs, uncontrolled hypertension continues to rise due to medication compliance issues and a failure to consider the diverse nature of hypertensive populations.
Key points are not available for this paper at this time.
Design
Review
Supports tailored antihypertensive strategies for diverse populations; extends RCT evidence beyond uniform treatment paradigms.
Hypertension affects >1 billion people worldwide. Complications of hypertension include stroke, renal failure, cardiac hypertrophy, myocardial infarction, and cardiac failure. Despite the development of various antihypertensive drugs, the number of people with uncontrolled hypertension continues to rise. While the lack of compliance associated with frequent side effects to medication is a contributory issue, there has been a failure to consider the diverse nature of hypertensive populations. Instead, we propose that hypertension can only be truly managed by precision. A precision medicine approach would consider each patient's unique factors. In this review, we discuss the progress toward precision medicine for hypertension with more predictiveness and individualization of treatment. We will highlight the advances in data science, omics (genomics, metabolomics, proteomics, etc), artificial intelligence, gene therapy, and gene editing and their application to precision hypertension.
No takes yet. Share an insight, caveat, or question.
Dzau et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: